Mp33-09 hourglass Deformity Portends a Lower Likelihood of Restoring Penetration and Preventing Surgery With Collagenase for Peyronie’s Disease

Heslop, Daniel; Helo, Sevann; Houlihan, Matthew; Bajic, Petar; Köhler, Tobias; Ziegelmann, Matthew

doi:10.1097/ju.0000000000000877.09

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 49 , 59 , 63 , 64 However, other studies did not find an association between calcification and treatment response. 50 , 65 , 66 Likewise, while longer duration of disease (>4 years) in the IMPRESS trial was associated with greater percentage improvements in penile curvature (− 40° vs − 14°) and PD bother scores (− 3.0 vs − 1.6), later studies did not corroborate these findings. 50 , 54 , 59 , 63 …”

Section: Intralesional Injection Therapiesmentioning

confidence: 93%

Peyronie’s Disease: An Outcomes-Based Guide to Non-Surgical and Novel Treatment Modalities

Reddy¹,

Dai²,

Song³

et al. 2023

RRU

View full text Add to dashboard Cite

The clinical landscape of Peyronie’s disease is everchanging. There has been growing interest in non-invasive therapeutic options that could assist patients with achieving a meaningful reduction in penile curvature without surgical intervention. These therapies are wide-ranging in terms of their mechanisms of action, efficacies, and short- and long-term safety profiles. Recently, an abundance of outcomes literature on longstanding and novel non-surgical treatment modalities has been published. For sexual medicine providers hoping to offer patients the most up-to-date and evidence-based treatments for the management of Peyronie’s disease, it can be challenging to gain a thorough understanding of this body of literature. In this clinical management review, the workup and current theories on the pathophysiology of Peyronie’s disease are reviewed, and the most recent outcomes data on the currently available non-surgical treatment modalities are presented. With an accurate understanding of the current landscape of Peyronie’s disease treatment, sexual health providers will be able to better evaluate and engage in evidence-based shared decision-making with their patients.

show abstract